Thursday, May 16, 2024

Cellomatics strengthens senior management team

Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has appointed Anand Krishna as senior director to oversee customer engagement and strategy and support its continued growth plans.

Anand brings over 25 years of executive leadership and field sales management experience in companies ranging from VC-funded dotcom start-ups, to managing sales across portfolios in tier 1 technology systems and operations integrators. His career has seen him lead and work with teams across the US, UK, Europe, India, and the Far East.

He now focuses on working with entrepreneurs across a diverse set of aspirational businesses to provide strategic support.

At Cellomatics, Anand will be a key member of the senior management team, overseeing customer care and management, sales, operations, and marketing.

Commenting on his appointment at Cellomatics, Anand said: “I have admired and followed Cellomatics from its foundation and I am delighted to be joining such a fast-growing and dynamic CRO.

“I am looking forward to the opportunity to work and learn from an energetic team of research scientists who play an active role in supporting the discovery and developments of treatments for diseases such as cancer, COPD and Alzheimer’s.

“The company is on an exciting growth trajectory, and my priority is to bring best practices and processes to the company to support the continued rapid growth.”

Cellomatics’ CEO and founder, Dr Shailendra Singh, adds: “We are on an ambitious growth curve which is fuelled by an increasing demand for our expertise in preclinical cell-based assay development in the oncology, respiratory, immunology, inflammation, and immuno-oncology therapeutic areas.

“As we grow, it is important to develop our infrastructure and bring in the expertise to support our commercial objectives. Anand’s wealth of experience in working with entrepreneurs will be an invaluable asset to Cellomatics, and I am delighted to welcome him to the team.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site and magazine but journalism costs money and we rely on advertising, print and digital revenues to help to support them.

With the Covid-19 pandemic having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites/magazines with either a small donation of even £1, or a subscription to our magazine, which costs just £33.60 per year, (inc p&P and mailed direct to your door) your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

As a subscriber, you will have unlimited access to our web site and magazine. You'll also be offered VIP invitations to our events, preferential rates to all our awards and get access to exclusive newsletters and content.

Just click here to subscribe and in the meantime may I wish you the very best.









Latest news

Related news

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close